dr. abigail a. barrow anupendra sharma imran nasrullah co ... · pitches that led to series a round...

June 2, 2011

Welcome to the Fourth Massachusetts Life Sciences Innovation Day!

Continuing our tradition, today’s program brings together all major organizations in the State to create an event that is focused on life sciences start-ups. This is where academia and business collide to create an event which supports and celebrates the commercialization of the research undertaken in Massachu-setts. We hope you find today’s program stimulating and we encourage you to use this day to actively meet people who make up the components of our great ecosystem in biotech, medtech and devices.

The Big Undiscovered Idea Poster Competition contains some of the greatest ideas that could impact medicine in the future. A key goal of the Competition is to exchange ideas and to connect the broader scientific community with those working in finance and policy. The earliest insight can, in time, foster an entire industry. Our poster competition will showcase fundamental advances in research so they can be seen by an extensive audience to help set the compass for where the industry could go in the future. Remember to invest your MALSI dollars in your favorite posters – it could help the inventors raise their first round of investment!

The main theme of our program today is “Building Biotech Backwards.” The members of the planning committee believe that you really need to think about the climate and global trends that are impacting the growth of life sciences companies before you embark on your own journey. We hope that this event will provide you with a road map for the commercialization of your technology before you take your first steps. Our keynote speakers and panelists represent a wide range of technologies and inventions. Some are leading companies as they launch new products and drugs into the market; others are just at the early stages of product development. Some have raised significant investments, while others have managed to achieve major milestones with very little funding. It is our hope that we all learn from their presenta-tions and comments.

And finally this year we have put a big emphasis on our closing reception. We will have many life science CEO’s joining the party and to undertake the final judging of the posters. Please be sure to meet them, pitch your ideas and tell them about your research and inventions.

We are particularly grateful to our Planning Committee for their help, support and entrepreneurial spirit in organizing this event. We would also like to thank all of our sponsors, particularly the Massachusetts Life Sciences Center and Partners HealthCare who are our lead sponsors for this event. All of our sponsors are as committed as we are to support the creation of new companies.

Thank you for being here today and we hope that you will participate in MALSI’s initiatives through its organizations as we continue to grow the Life Sciences in the Commonwealth.

Anupendra Sharma Co-Chair MALSIInvestment Partner, Siemens Ventures

Dr. Abigail A. BarrowCo-Chair MALSIDirector, Massachusetts Technolgy Transfer Center

Imran Nasrullah Co-Chair MALSI Cheif Business Officer,MassBio

4th AnnualMassachusetts Life Sciences Innovation Day

ii

Table of ContentsFloor Plan – Harvard Club of Boston .................................................................................. v

Conference Agenda ............................................................................................................. vi

Speaker Biographies .............................................................................................................. 9

Keynotes ............................................................................................................................. 11Benjamin Conway ......................................................................................................................................11Richard Roberts .........................................................................................................................................11Todd Zion ..................................................................................................................................................11

Introductions ....................................................................................................................... 12Abigail Barrow ..........................................................................................................................................12Robert K. Coughlin ..................................................................................................................................12Robert J. Creeden ......................................................................................................................................13Anupendra Sharma ...................................................................................................................................13

Panelists ............................................................................................................................... 14Richard Anders .........................................................................................................................................14Patrick Anquetil ........................................................................................................................................14Edward E. Berger .......................................................................................................................................14Virginia Carnahan .....................................................................................................................................15Jessica Duda ...............................................................................................................................................15Johannes Fruehauf ......................................................................................................................................16Howard Golub ...........................................................................................................................................16Richard S. Melanson .................................................................................................................................16Ben Rubin ..................................................................................................................................................17Sameer Sabir ...............................................................................................................................................17Aaron Sandoski .........................................................................................................................................17John J. Schwartz .........................................................................................................................................17John Tagliamonte .......................................................................................................................................18

Open Discussions Speakers ................................................................................................. 19Neculai Archip ...........................................................................................................................................19Michelle Basil ............................................................................................................................................19Kees Been ...................................................................................................................................................19Jeff Behrens ................................................................................................................................................20Richard Berenson .......................................................................................................................................20Ajit Bharti ..................................................................................................................................................21Kevin J. Bitterman .....................................................................................................................................21Scott Brown ...............................................................................................................................................21Angela Chen ...............................................................................................................................................22

June 2, 2011Harvard Club of Boston

iii

Chip Clark .................................................................................................................................................22Bill Edelman ...............................................................................................................................................22Greg Erman ................................................................................................................................................23Alexandra Glucksmann .............................................................................................................................23Manijeh Goldberg ......................................................................................................................................23Andy Golden ..............................................................................................................................................24Jeremy Halpern ..........................................................................................................................................24Michael W. Henry .....................................................................................................................................24Andrew Jay .................................................................................................................................................25Julius Knowles ............................................................................................................................................25Jennifer King ..............................................................................................................................................25Stan Lapidus ...............................................................................................................................................26Christopher Leo .........................................................................................................................................26Ali Munawar ...............................................................................................................................................26Imran Nasrullah ........................................................................................................................................27Pamela Norton ...........................................................................................................................................27Eric Olson ..................................................................................................................................................27Christopher M. Palatucci ...........................................................................................................................28Sam (Bo) Pasternack ..................................................................................................................................28Josh Tolkoff ...............................................................................................................................................28Roger Tung .................................................................................................................................................29James H. Velema .........................................................................................................................................29Geoff Whitehead .......................................................................................................................................29

MALSI Day Planning Committee ..................................................................................... 31

Sponsors, Affiliates & Organizers ....................................................................................... 33Gold Sponsor .............................................................................................................................................34Silver Sponsor ............................................................................................................................................35Conference Supporters ..............................................................................................................................36Organizers ..................................................................................................................................................38In association with .....................................................................................................................................42

Poster Presenters ................................................................................................................. 43Abazyme LLC ................................................................................................................................................ 45AcuityBio Inc. ................................................................................................................................................ 45Advirna .......................................................................................................................................................... 45Beth Israel Deaconess Medical Center .......................................................................................................... 45Boston University .......................................................................................................................................... 45Boston University .......................................................................................................................................... 46Brandeis University ........................................................................................................................................ 46Brandeis University ........................................................................................................................................ 46Cellgenex Diagnostics ................................................................................................................................... 46Cellthera, Inc. & Worcester Polytechnic Insitute.......................................................................................... 46CMB Science Inc. .......................................................................................................................................... 47


iv

Diagnostics for All ......................................................................................................................................... 47Harvard Medical School ................................................................................................................................ 47Harvard University ........................................................................................................................................ 47HepatoChem .................................................................................................................................................. 47Karyopharm Therapeutics ............................................................................................................................. 47Massachusetts General Hospital .................................................................................................................... 48Massachusetts Institute of Technology .......................................................................................................... 48Pharyx Inc. ..................................................................................................................................................... 48Physical Sciences Inc. ..................................................................................................................................... 48Renu Therapeutics LLC ................................................................................................................................ 48Seign LLC ..................................................................................................................................................... 48University of Massachusetts-Amherst ........................................................................................................... 49Worcester Polytechnic Institute..................................................................................................................... 49Worcester Polytechnic Institute..................................................................................................................... 49Worcester Polytechnic Institute..................................................................................................................... 49Worcester Polytechnic Institute..................................................................................................................... 49Worcester Polytechnic Institute, Columbia University & Stony Brook University ..................................... 50Wyss Institute, Harvard University ............................................................................................................... 50Wyss Institute, Harvard University ............................................................................................................... 50Wyss Institute, Harvard University ............................................................................................................... 50

Innovator’s Marketplace Exhibitors .................................................................................... 51Life Science Products and Services ...........................................................................................................52Entrepreneurship Support .........................................................................................................................52Angel & Startup CEO Bar .........................................................................................................................53Funding ......................................................................................................................................................53Professional Services ..................................................................................................................................53


v

Floor Plan – Harvard Club of Boston


vi

TIME SESSION

Foyer Harvard Hall

8:00 AM Registration & Breakfast

Harvard Hall

9:00 AM Welcome by Conference Co-Chairs Abigail Barrow, Massachusetts Technology Transfer Center and

Anupendra Sharma, Siemens Venture Capital State of the Union Address

by Benjamin Conway, Managing Director, Johnston Blakely & Company

9:15 AM Keynote Address by Nobel Laureate Sir Richard Roberts

10:00 AM Overview of the Day and Call for Afternoon Discussion TopicsAnupendra Sharma, Siemens Venture Capital

Foyers on the 1st and 2nd Floors

10:15 AM NETWORKING BREAK / POSTER & STARTUP SHOWCASE

Massachusetts Room Aesculapian Room

10:45 AM Funded Biotech Founders: Pitches that led to Series A Round

Johannes Fruehauf, Vithera LabsRichard Melanson, HiLo Microscopy

Jay Schwartz, Acuitybio

Moderator: John Tagliamonte, Selventa

Funded Medtech/Diagnostics Founders: Pitches that led to Series A Round

Patrick Anquetil, SynapDx Jessica Duda, NinePoint Sameer Sabir, Momelan

Ben Rubin, ZeoModerator: Aaron Sandoski, Norwich Ventures


11:45 AM NETWORKING BREAK / POSTER & STARTUP SHOWCASE

Harvard Hall - Lunch

12:00 PM Recognition of UMass President Jack Wilson by Robert K. Coughlin, MassBio Council

Introduction: Robert Creeden, Partners HealthCareKeynote: The Story of Smart Cells by Todd Zion, President and CEO

Harvard Hall

1:15 PM Panel: Building Biotech Backwards

Ed Berger, Larchmont Strategic Partners Bruce Booth, Atlas VentureVirginia Carnahan, VertexHoward Golub, Care-Safe

Moderator: Richard Anders, MA Medical Angels


vii

TIME SESSION


2:15PM NETWORKING BREAK / POSTER & STARTUP SHOWCASE

Massachusetts Room Aesculapian Room Bartlett Room

2:45 PM Careers outside of Academia: Discussion

Neculai Archip, Harvard Radiology

Manijeh Goldberg, Privo Andrew Golden, DaktariChris Palatucci, Palatucci

Executive Search Geoff Whitehead, Flagship

VentureModerator: Angela Chen,

Roche

Intellectual Property for Start-ups: Open Discussion

Scott Brown, NovartisBo Pasternack, MIT

Moderator: James Velema, Lathrop & Gage

How to start a Diagnostics Company:

Open Discussion

Ajit Bharti, PredictusMichael Henry, Athena

DiagnosticsStan Lapidus, SynapDxModerator: Anupendra

Sharma, Siemens Venture Capital

3:35 PM Hot Diseases: Open Discussion

Kees Been, EnVivoChip Clark, Genocea

Eric Olson, Vertex Moderator: Kevin Bitterman, Polaris

Partnering with Pharma/Biotech: Open Discussion

Jeff Behrens, Edimer Giulio Draetta, Dana Farber Jennifer King, Shire Human

Genetic Therapies Jay Knowles, Novartis

Chris Leo, Back Bay Life Science

Early Money: Angels & Grants: Open Discussion

Rick Berenson, MA2Pam Norton, Mass

LifeSciences CenterModerator: Jeremy

Halpern, TCN

4:15 PM How to start a Biotech Company: Open

Discussion

Alexandra Glucksmann, Cerulean Pharma

Ali Munawar, Novira Therapeutics

Roger Tung, Concert PharmaceuticalsModerator: Imran

Nasrullah, MassBio

How to start a Medtech Company: Open Discussion

Bill Edelman, MindChildGreg Erman, Novo Medical

Josh Tolkoff, Ironwood EquityModerator: Michelle Basil, Nutter

Inside a VC firm: Case and Open Discussion

Andrew Jay, Siemens Venture Capital

Harvard Hall

5:00 PM Reception / Innovators’ Marketplace / Poster and Invention Awards


8 Biographies


Biographies 9

Speaker BiographiesKeynotes ............................................................................................................................. 11

Benjamin Conway ............................................................................................................... 11Richard Roberts .................................................................................................................. 11Todd Zion ............................................................................................................................ 11

Introductions ....................................................................................................................... 12

Abigail Barrow .................................................................................................................... 12Robert K. Coughlin ........................................................................................................... 12Robert J. Creeden ................................................................................................................ 13Anupendra Sharma ............................................................................................................. 13

Panelists ............................................................................................................................... 14

Richard Anders ................................................................................................................... 14Patrick Anquetil ................................................................................................................. 14Edward E. Berger ................................................................................................................. 14Virginia Carnahan ............................................................................................................... 15Jessica Duda ......................................................................................................................... 15Johannes Fruehauf ............................................................................................................... 16Howard Golub..................................................................................................................... 16Richard S. Melanson ........................................................................................................... 16Ben Rubin ............................................................................................................................ 17Sameer Sabir ........................................................................................................................ 17Aaron Sandoski .................................................................................................................. 17John J. Schwartz ................................................................................................................... 17John Tagliamonte ................................................................................................................ 18

Open Discussions Speakers ................................................................................................. 19

Neculai Archip .................................................................................................................... 19Michelle Basil ..................................................................................................................... 19Kees Been ............................................................................................................................ 19Jeff Behrens .......................................................................................................................... 20Richard Berenson ................................................................................................................ 20Ajit Bharti ............................................................................................................................ 21Kevin J. Bitterman ............................................................................................................... 21Scott Brown ......................................................................................................................... 21


10 Biographies

Angela Chen ........................................................................................................................ 22Chip Clark ........................................................................................................................... 22Bill Edelman ........................................................................................................................ 22Greg Erman ......................................................................................................................... 23Alexandra Glucksmann ....................................................................................................... 23Manijeh Goldberg ............................................................................................................... 23Andy Golden ....................................................................................................................... 24Jeremy Halpern .................................................................................................................... 24Michael W. Henry .............................................................................................................. 24Andrew Jay........................................................................................................................... 25Julius Knowles ..................................................................................................................... 25Jennifer King ....................................................................................................................... 25Stan Lapidus ........................................................................................................................ 26Christopher Leo .................................................................................................................. 26Ali Munawar ........................................................................................................................ 26Imran Nasrullah ................................................................................................................. 27Pamela Norton .................................................................................................................... 27Eric Olson ............................................................................................................................ 27Christopher M. Palatucci .................................................................................................... 28Sam (Bo) Pasternack ........................................................................................................... 28Josh Tolkoff ......................................................................................................................... 28Roger Tung .......................................................................................................................... 29James H. Velema .................................................................................................................. 29Geoff Whitehead ................................................................................................................ 29


Biographies 11

Speaker Biographies

Keynotes

Benjamin ConwayFounder and Managing Director, Johnston Blakely & CompanyBenjamin Conway is founder and managing director of Johnston Blakely & Company. Johnston Blakely is a Boston-based life science focused investment bank providing M&A advisory and private equity placement services to biopharmaceutical, medical device and diagnostic companies as well as companies engaged in the ancillary service sectors. Prior to Johnston Blakely, Mr. Conway was Group Head, Biotechnology Bank-ing for the investment bank Adams, Harkness and Hill. He has also held positions with Abbott Laboratories and Bain & Company.

Richard RobertsChief Scientific Officer, New England BiolabsSir Richard Roberts is the Chief Scientific Officer at New England Biolabs, Ipswich, Massachusetts. He re-ceived his Ph.D. from the University of Sheffield in Organic Chemistry and then moved to Harvard University in 1969 to work with Professor J.L. Strominger. In 1972 he moved to Cold Spring Harbor Laboratory under Dr. J.D. Watson eventually becoming Assistant Director. He first worked on the newly discovered Type II restric-tion enzymes in 1972 and in the next few years more than 100 such enzymes were discovered and charac-terized by his group. Cloning of the genes for several RM systems followed and studies of these enzymes have been a major research theme. Work on Adenovirus-2 led to the discovery of split genes and mRNA splicing in 1977 and he received the Nobel Prize in Physiology of Medicine in 1993. The 35,937 nucleotide DNA sequence of the Adenovirus-2 genome was completed in 1985. This required the extensive use of com-puter methods, both for the assembly of the sequence and its subsequent analysis and many of the key pro-grams required were first written by his group. The further development of computer methods for protein and nucleic acid sequence analysis continues to be a major research focus. The field of DNA methyltransferases is also an area of active research interest and crystal structures for the HhaI methyltransferase both alone and in complex with DNA were obtained in collaboration with Dr. Xiaodong Cheng. From this work came the discovery of base flipping in 1993 whereby the target cytosine base that becomes methylated is flipped completely out of the helix so that it is accessible for chemical reaction. A consuming interest at present is the semi-automatic identification of restriction enzyme and methylase genes within the GenBank database and the development of rapid methods to assay function.

Todd ZionPresident and CEO, SmartCells Inc.Todd C. Zion, Ph.D. founded SmartCells, Inc. (Beverly, MA) in 2003 to develop SmartInsulin TM, the first glucose-regulated, injectable formulation for treating diabetes. As President and CEO since the compa-ny’s founding, Todd was instrumental in raising over $9.5M in equity financing from individual investors and over $10M in government grants to support basic research and clinical development. In Decem-ber 2010, Merck and Co. acquired SmartCells for over $500M in cash and clinical milestone payments. Dr. Zion developed the SmartInsulin TM technology as part of his doctoral thesis work in Chemical Engineer-ing at the Massachusetts Institute of Technology. At M.I.T., Todd won the Robert P. Goldberg Grand Prize in the 2003 M.I.T. $50K Entrepreneurship competition. Prior to enrolling at M.I.T., he worked as a polymer development engineer at Eastman Kodak, where he invented and was issued several patents for the novel synthesis of polymer particles for imaging applications. Todd graduated from Cornell University summa cum laude with a B.S. in Chemical Engineering.


12 Biographies

Introductions

Abigail Barrow Founding Director, Massachusetts Technology Transfer Center and Conference Co-Chair Abigail Barrow is the Founding Director of the Massachusetts Technology Transfer Center (MTTC). The MTTC is state funded and supports technology transfer activities from public and private research institutions to companies in Massachusetts. The Center works with technology transfer offices at all research institu-tions; faculty, researchers, and students who have commercially promising ideas; and companies across the Commonwealth. Prior to joining the MTTC, Dr. Barrow served as managing director of William J. von Liebig Center at the University of California San Diego (UCSD). The von Liebig Center was created in 2001 to support the commercialization of research being performed in the Jacobs School of Engineering. Dr. Bar-row worked in a variety of roles at UCSD CONNECT from 1990 to 2001. CONNECT’s programs focused on supporting early stage high-tech and biotech companies and in particular helping them raise funding from venture capitalists and corporate partners. Dr. Barrow has also worked with other regions where the CON-NECT program has been successfully replicated, including Scotland and Scandinavia. Dr. Barrow is a Fellow of UCSD’s Beyster Institute and an Xconomist for Xconomy.com.

Robert K. Coughlin President & CEO, Massachusetts Biotechnology Council As President and CEO of the Massachusetts Biotechnology Council, Bob’s mission is to foster a positive environment that enables each biotechnology company to achieve its full potential in Massachusetts, making the state a world center for biotechnology. He is very familiar with all areas of the Massachusetts life sci-ences super cluster and is a passionate advocate for research and the biotechnology community. Bob has spent his career in both the public and private sectors, most recently serving as Undersecretary of Economic Development within Governor Deval Patrick’s administration in 2007. Prior to that, he was elected as State Representative to the 11th Norfolk district for three terms. In the legislature both healthcare and economic development were his priorities. In the world of business he specialized in the environmental services indus-try and moved on to capital management and venture capital. He has held senior executive positions in both fields. He is a graduate of the Massachusetts Maritime Academy where he majored in Marine Engineering, and is a Lieutenant in the United States Naval Reserve. Coughlin has also been active in the community, having served on the boards of the Massachusetts Maritime Academy and Beth Israel Deaconess Hospital. He has served as the honorary chairman of the Great Strides Cystic Fibrosis Walk since 1996. In 2009 he co-chaired the Children’s Hospital Boston signature event, Champions for Children’s.


Biographies 13

Robert J. CreedenManaging Partner, Partners Innovation Fund at Partners HealthCare Bob is Managing Director for the Partners Innovation Fund at Partners HealthCare, where he oversees the creation and launching of new ventures generated from Partners innovative research discoveries. Bob has spent more than twenty-five years commercializing new technologies and promoting emerging businesses, including fifteen years early stage venture capital investing experience and culminating in his 2004 appoint-ment by Partners to establish the Center for Innovative Ventures. In 2007, Bob and his team led the launch of the Partners Innovation Fund to accelerate technologies to market. Previously, he was a general partner at Egan-Managed Capital, a $150 million dollar Boston-based venture fund, after having served as Vice Presi-dent of the Massachusetts Technology Development Corporation, a 25-year-old early stage venture firm that funds technology-based companies in Massachusetts. Earlier in his career, he gained strategic operating expertise as a COO/CFO with start-up ventures and as a management consultant with Control Data Busi-ness Advisors. He holds an AB in Economics from Holy Cross College and an MBA from Suffolk University. While serving in a leadership role on the boards of portfolio companies and developing strong relationships with co-investors from New England and across the country, Bob has reviewed more than 2000 business plans and invested in more than 40 companies. His portfolio has included companies developing leading-edge technologies in semiconductors, software, telecommunications, medical devices, manufacturing and advanced materials. He has extensive experience putting together syndicates of investors, corporations and third parties to fund technology companies through investment, partnership, joint development and research agreements.

Anupendra Sharma Partner, Siemens Venture Capital and Conference Co-Chair Anupendra Sharma is Partner at Siemens Venture Capital investing in healthcare (devices, diagnostics, software and services). Anupendra is an investor in China Diagnostics and Cylex. He is a former investor in Sequenom (NASD: SQNM) and BioImagene (acquired by Roche). Prior to Siemens Venture Capital, Anu-pendra helped companies go public and raise capital, and completed $5 billion in M&A transactions at JP-Morgan, Salomon Smith Barney and Siemens. Anupendra also worked in strategy consulting for McKinsey London, and Product Development Finance for Ford Europe, where he was a member of the core team that set-up Ford in China and India. Anupendra is a Charter Member of TiE Boston, Founder of The Leadership Program for Startups CEOs, and mentor to early-stage life sciences companies in New England. Anupen-dra founded the Center for Entrepreneurial Leadership at BITS Pilani, and is Founding Advisor to Peking University’s Venture Capital Association. He also started the Massachusetts Life Sciences Startup Initiative to accelerate the pace of startups in the Commonwealth, and advises government and related agencies on policy matters related to startups in the Commonwealth. Anupendra holds an MBA from Cornell University, MS in Accounting & Finance from Manchester Business School, Masters in Economics and Bachelors in Instrumentation Engineering from BITS Pilani, India.


14 Biographies

Panelists

Richard Anders Founder and Executive Director, MA Medical Angels (MA2)Richard Anders, is a lawyer turned entrepreneur. In 1984 he founded Jurisoft, which he later sold to Lexis/Nexis. He later was the publisher of Boston Digital Industry and New York Digital Industry, and currently is Managing Director of Rubin/Anders Scientific. Richard is a trustee of the Boston Museum of Science, a member of the MIT/Harvard Medical School HST program advisory council where he helps teach a course on the biomedical enterprise, and a trustee of the Boston Biomedical Research Institute. He is a member of the Institutional Review Board at the Dana Farber Cancer Center. He founded the angel groups Launchpad and in 2008, MA Medical Angels (MA2), one of the country’s only angel groups focused exclusively on life sciences. Richard is a graduate Summa Cum Laude in mathematics from Harvard and holds a J.D. from Harvard Law School.

Patrick Anquetil Co-Founder, SynapDx Patrick is a Co-Founder of SynapDx where he is the Director of Strategic and Process Planning. SynapDx provides laboratory-testing services to physicians who evaluate children for developmental disorders. Patrick began his career as a science and nanotechnology equity research analyst at Susquehanna International Group. Subsequently he became the founding CEO of Aretais, a medical device startup issued from MIT and developing a non-invasive blood glucose monitor. He received his PhD at MIT in Bio-Instrumentation, an MBA from Harvard Business School and a Master’s degree from the ETH in Zurich.

Edward E. BergerPrincipal and Founder, Larchmont Strategic AdvisorsEdward E. Berger, Ph.D., Principal and Founder of Larchmont Strategic Advisors, has nearly 30 years experience in health services, medical technology and life sciences reimbursement, regulatory poli-cy, quality improvement and strategic planning. As a consultant he helps life sciences companies cre-ate and implement integrated strategies to address the obstacles and opportunities they face in their ef-forts to secure regulatory clearance and optimal reimbursement for new or evolving technologies. Focusing on issues that arise at the intersection of public policy and corporate strategy development, Dr. Berger helps clients to deal effectively with the strategic challenges posed by the rapidly evolving health-care regulatory and policy environment. He has worked to provide regulatory and reimbursement policy analysis, planning and strategy for a variety of companies in fields including mechanical circulatory sup-port, cardiology, orthopedics, neural monitoring and neuromodulation, gastrointestinal surgery, pulmonary medicine, nuclear medicine, diagnostic imaging, clinical laboratory testing, and personalized medicine. Prior to founding his consultancy, Dr. Berger served on the senior management teams of Fresenius Medical Care, Thermo Cardiosystems and ABIOMED. His responsibilities in these positions covered functional areas including government relations, strategic planning, corporate compliance, continuous quality improvement programs, media and investor relations, and strategically sensitive corporate communications. In addition to his consulting practice, he currently serves as a Director of Atanse, Inc., a Belmont MA developer of innova-tive neurosurgical instruments, as a mentor in Boston University’s IGNITE program, and as President of the Medical Development Group, a 400 member professional association of individuals professionally committed to the medical device and related life sciences business sectors.


Biographies 15

Bruce BoothGeneral Partner, Atlas VentureBruce Booth is a General Partner at Atlas Venture. Prior to Atlas Venture, Bruce was a Principal at Caxton Health Holdings L.L.C., a healthcare-focused investment firm. He focused on the firm’s private equity activi-ties, ranging from early stage venture capital through late stage buyouts. Prior to joining Caxton Health, he was an Associate Principal at McKinsey & Company, a global strategic management consulting firm, where he focused on R&D productivity, corporate strategy, and business development issues for several major biophar-maceutical companies. While at McKinsey, he also co-led the Firm’s international scholars recruiting efforts. Bruce works closely with Atlas Venture portfolio companies ARCA Discovery, Archemix, Conxcys, Dynogen, NxStage Medical, Prestwick Pharmaceuticals, Proprius Pharmaceuticals, SGX Pharmaceuticals (NASDAQ: SGXP) and Zafgen. He serves on the Board of Zafgen.

As a British Marshall Scholar, Bruce earned a Doctorate in Molecular Immunology from the Oxford Uni-versity’s Nuffield Department of Medicine and the Weatherall Institute of Molecular Medicine. His research focused on viral and tumor immune surveillance, and how the immune system responds to intracellular pathogenesis. During his graduate studies at Oxford, he also received the Overseas Research Fellowship and served as junior dean of Trinity College. Prior to graduate studies, he worked on President Clinton’s Do-mestic Policy Council in the National Office of AIDS Policy. He received a Bachelor of Science degree with highest honors in Biochemistry from the Pennsylvania State University, where he was an Evan Pugh Scholar. He currently serves on the New York Academy of Medicine Board of Trustees, and is an active member of the Council on Foreign Relations. Bruce has also authored numerous scientific papers and reviews, including several in Nature Reviews Drug Discovery.

Virginia CarnahanVice President, Commercial Strategy and Management, Vertex PharmaceuticalsVirginia has been at Vertex for the past 13 years providing commercial insights and strategies on our com-pounds starting in research through development. She leads the CF Marketing and Sales, New Product Planning and Strategy, and Health Economics. She has worked on the Cystic Fibrosis Program for the past 5 years and her team is building the strategies to support the launch of VX 770. Prior to Vertex, Virginia worked for 8 years in marketing at Schering Plough in the Oncology/Biotech business. Virginia received her MBA from Duke University, Fuqua School of Business.

Jessica DudaSenior Director, Business Development and Strategic Planning, NinePointJessica Duda is a member of NinePoint’s founding team, having served as project director during the com-pany’s initial development at Third Rock Ventures. She previously worked at Cyberkinetics Neurotechnology Systems, Inc., a medical device company focused on neurological disorders, where she held responsibilities in corporate development, regulatory, and manufacturing. Prior to that, she was an associate at Polaris Ven-ture Partners, where she developed strategic business plans for companies in a variety of industries, and a research analyst for DePuy Orthopaedics. Jessica earned an AB degree from Dartmouth College and BE, MS, and MEM degrees from the Thayer School of Engineering at Dartmouth College.


16 Biographies

Johannes FruehaufFounder and President, ViThera Dr. Fruehauf has a long track record in innovative research and successful research organization. Before starting ViThera, he helped build Cequent Pharmaceuticals in 2006 and served as Cequent’s Head of R&D until 2009. He did his postdoc with Dr. Chiang Li at the Beth Israel Deaconess Medical Center and invented the bacterial RNAi technology transkingdom RNA interference, the only RNAi therapeutic targeting the gas-trointestinal tract. He serves as a consultant to a number of biotechnology companies, including Cequent Pharmaceuticals and Aura Biosciences. Dr. Fruehauf is the author of over 20 peer reviewed publications and named inventor on 9 patents related to RNA interference and bacterial therapeutics.

Howard GolubPresident, Care-Safe Dr. Golub was one of the founding partners and CEO of a number of healthcare companies. He has broad experience in the strategic and execution issues related to bringing medical products to market. In addition, he was also one of the founders of CareStat, a full-service clinical trial consulting company. He is now an independent consultant for the pharmaceutical and medical device industry.

In 1980 Dr. Golub founded PDS Inc., a medical computer-based diagnostic device company where he de-veloped software for automated analysis of infant cardiorespiratory recordings; PDS was acquired in 1995. In 1991 Dr. Golub co-founded Cry Research Inc. where he developed and performed clinical studies utilizing a computer-based signal processing system he developed for automated analysis of the acoustical charac-teristics of the infant cry. In 1995, he co-founded DxTek Inc. where technology from his patent was used for a device that permits continuous, cuffless, non-invasive measurement of blood pressure (based on assess-ment of pulse transit time and photoplethysmographic wave shape). In 1996, he was a founder and Presi-dent of CareStat Inc., a full service clinical trial consulting company that was acquired in 2005. Dr. Golub has served as Principal Investigator on two large NICHD sponsored studies of infant cry analysis (in relation to SIDS and as a predictor of neurodevelopmental outcome). Dr. Golub has a current appointment at the Harvard-MIT Division of Health Sciences and Technology as Senior Lecturer, a Distinguished Fellow at the Center for Biomedical Innovation at MIT, and an adjunct faculty appointment at Boston University School of Public Health in Epidemiology and Biostatistics.

Richard S. Melanson Founder & CEO, HiLo Microscopy Inc.Mr. Melanson has held various senior management positions at venture capital start-ups and large multina-tional corporations. Mr. Melanson has been a President/CEO/COO for the past 20+ years. Mr. Melanson has been CEO of two venture capital start-ups, President of two mid sized companies and Division President at two large corporations; Thermo Fisher Scientific and Philips Electronics N.V. Mr. Melanson’s professional experience include roles of President & CEO of BlueShift Technologies; President of GlenRose Partners; President & CEO of ElectroScan Corporation; and Vice President of AMRAY. Mr. Melanson received a Bach-elor degree in Business Administration from University of Massachusetts (Lowell Technological Institute) and a Masters Degree in Finance from Bentley College.


Biographies 17

Ben RubinChief Technology Officer and Co-Founder, Zeo Inc. Ben co-founded Zeo, the company behind the world’s first personal sleep coach, at Brown University in 2003 and now serves as the CTO. Ben aims to change how we measure and talk about sleep and is constantly exploring methods of self-improvement. Ben holds a BS in Computer Engineering from Brown.

Sameer SabirCo-Founder & CEO, MomellanSameer is a co-founder and CEO of MoMelan Technologies, a venture and angel-backed company develop-ing a novel enabling technology facilitate skin grafting as a treatment modality in the office-based setting. The company was co-founded with Prof. Rox Anderson, inventor of laser hair removal. Sameer is winner of the 2008 national Venture Capital Investment Competition. Prior to business school, in 2003 Sameer founded Cinnabar Consulting, a UK-based corporate & business development consulting firm servicing Scandinavian life-sciences companies, primarily assisting them with generating business development opportunities in the US. Prior to that Sameer worked in Life Sciences Investment Banking with JP Morgan and then Com-merzbank Securities. Sameer has a B.Sc. in Immunology from University College London (UCL), and was a student on the Harvard-MIT Biomedical Enterprise Program, where he received an MBA from MIT Sloan and an SM from the Harvard-MIT Division of Health Sciences & Technology.

Aaron Sandoski Managing Director, Norwich Ventures Aaron Sandoski is the Managing Director of Norwich Ventures, an early-stage venture capital firm special-izing in medtech. He is involved in all facets of the investment process and draws from a broad background in healthcare and start-up operations to support portfolio companies. Prior to founding Norwich Ventures, Aaron worked for DEKA, the engineering think tank of Dean Kamen, where he helped develop partnerships and formulate business plans for emerging technologies. Aaron has also worked in start-up operations where he helped launch a subsidiary of Express Scripts and helped launch a venture-backed payments company. Both companies were acquired in transactions totaling over $500 million. He began his career as a con-sultant at McKinsey & Company, where he advised healthcare clients ranging from leading medical device companies to a rural hospital system. Aaron serves as a board member of MedTech IGNITE, an initiative of the Massachusetts Medical Device Industry Council (MassMEDIC) for nurturing early-stage medical device entrepreneurs. He is also co-author of How the Wise Decide, a book on decision-making in business (Crown Business, 2008). Aaron earned an MBA from Harvard Business School and graduated summa cum laude from Dartmouth College with a double A.B. in Chemistry and Economics.

John J. SchwartzCSO & President, AcuityBio John J. Schwartz, PhD. has over 20 years in Life Sciences technology development (medical device, diag-nostics, biotech, and drug delivery technologies). Jay has led high-level biomedical research at both MIT Center for Biomedical Engineering and at small life sciences companies. He has experience and expertise in the formation and growth of Life Sciences companies from initial technology development through proof of concept, business development and exit. He is experienced in private equity fundraising and has succeeded in securing multiple U.S. government grants. His last company engeneOS (later bought by ADNEXUS) was venture backed and sold to Bristol Myers for >8X ROI. He has been an active MIT VMS Mentor, angel in-vestor through Keiretsu Forum and Boston Harbor Angels and early stage life sciences company business


18 Biographies

consultant for more than nine years. He is presently CSO & President of a AcuityBio a Boston-Based startup developing a drug eluting mesh which prevents lung cancer recurrence. Jay received his Ph.D. in Biochem-istry and Molecular Biology from New York Medical College, and pursued Postdoctoral work at Harvard and MIT in cardiovascular medicine.

John TagliamonteSenior Vice President of Corporate Development, SelventaBefore joining Selventa, Mr. Tagliamonte was VP, Business Development at Anchor Therapeutics where he led a transformative partnership with Johnson & Johnson that enabled the company’s Series B financing. Prior to Anchor Therapeutics, he led strategy and corporate development with ImmunoGen to advance the company’s targeted anti-cancer therapeutics candidates through the clinical programs as well as evaluated and optimized Intellectual Property estates. He previously held senior strategic corporate development roles at Millipore, Laureate Pharma and Johnson & Johnson, and managed dozens of partnerships collectively valued over $1B. He earned his BS from Tufts University and his MBA from Boston College.


Biographies 19

Open Discussions Speakers

Neculai ArchipFaculty Member, Harvard Radiology & Joining Graduate Leadership, SiemensNeculai will soon join the Siemens Graduate Program, MBA track, a two-year accelerated global leadership program with three rotations in different function, business, and geographic areas. Prior to joining Siemens Healthcare, Neculai interned at Siemens Venture Capital. He has contributed to full-cycle investments in medical device, diagnostics, and healthcare IT ventures. In addition, he has been assisting portfolio compa-nies with their growth strategies, e.g. M&A efforts.

He has also prepared strategy and innovation reports on areas of interest for 2011 investments. Dr. Archip has been a Faculty member in the Department of Radiology at Brigham and Women’s Hospital and Harvard Medical School since March 2005, where he raised $2 million in funding from NIH and has reviewed applications for NIH funding in excess of $3 million. Earlier in his career, Neculai worked for one year in a tech start-up and has consulted with a few other early stage ventures both in technology and healthcare (including a Synthes spinoff). During his MBA program, Neculai has completed a 6-month consulting engagement for Microsoft Corporation. Neculai holds an MBA degree earned from Cornell University, a PhD in biomedical imaging from the Univer-sity of Neuchâtel, Switzerland, and a Bachelor in Computer Science from University Al. I. Cuza Iasi, Roma-nia. Neculai has co-founded of two internet startups, has lived in 4 countries (Romania, Switzerland, Canada and US), speaks fluently 4 languages and is conversational in a few others.

Michelle Basil Partner, Nutter McClennen & Fish LLP Michelle Basil is a partner in the Business Department and chair of the firm’s Hiring Committee. She focuses her practice on corporate and securities law, including mergers and acquisitions, securities offerings, ten-der offers and going private transactions. She represents clients in a broad range of industries, including financial services, life sciences and high technology. Michelle counsels clients regarding ongoing reporting requirements of publicly-traded companies, securities compliance, corporate governance, equity compensa-tion, and various other matters affecting publicly-traded companies and their officers and directors. She also advises private companies regarding formation, ongoing business issues and venture financing. A member of Nutter’s Banking and Financial Services group, she has significant experience representing banks in cor-porate and regulatory matters. She is a member of the Boston Bar Association and frequently lectures on securities law issues. During law school, Michelle served as associate editor of Ecology Law Quarterly and as a member of the Moot Court Board.

Kees BeenPresident and Chief Executive Officer, EnVivoKees Been has served as president and chief executive officer since 2005 and brings more than 15 years of experience to EnVivo. Prior to joining EnVivo, Kees was chief executive officer of Bionaut Pharmaceuticals, a biotechnology company using a proprietary cell-based discovery platform to advance drug candidates for cancer and inflammation. Prior to his work at Bionaut, Kees spent four years at Biogen where he directed the Oncology Business Unit and, as senior vice president of business development, led all of Biogen’s deal-making efforts and portfolio management activities. Major deals he oversaw include the collaborations with Elan on Antegren® (now Tysabri®), with ICOS on the oral LFA-1 antagonist, and with EOS Biotechnology on breast cancer target discovery. Before his work with Biogen, Kees held executive positions with Mon-


20 Biographies

santo Life Sciences Company, involving corporate modification projects and large growth strategies in Latin America. Prior to that, Kees worked at Gemini Consulting where he last served as vice president and was responsible for building the pharmaceuticals practice. He began his career as a scientist on the Interferon-gamma project at Biogen in Geneva, Switzerland. He earned an M.B.A. degree from INSEAD in France and a B.S. degree in Molecular Biology and Process Engineering from the University of Agriculture in Holland.

Jeff BehrensSenior Director, Business Development, Edimer Pharmaceuticals Jeff Behrens is currently Senior Director, Business Development and Operations at Edimer Pharmaceuticals which is focusing on developing a treatment for a rare genetic disease – XLHED (X-linked hypohidrotic ecto-dermal dysplasia). Edimer is funded by Third Rock Ventures in Boston and VI Partners in Switzerland. Jeff has broad responsibilities with manufacturing, finance, operations, and business development/alliance/partnering. Formerly, Jeff was Director, Strategic Alliances at Alnylam and Co-founder and Head of Business Opera-tions of “BI3” - The Biogen Idec Innovation Incubator - where he founded and launched two companies funded by Biogen Idec – Escoublac and Provasculon - working on diabetes and cardiovascular indications . In 2003 Jeff sold his health-care IT company, The Telluride Group, to mindSHIFT Technolo-gies, a Fidelity-funded rollup. Telluride was an angel financed managed services provider (MSP). Jeff is currently an Entrepreneur In Residence at the MIT Sloan Entrepreneurship Center, a member Mass Medical Angels, and a mentor with MIT’s Venture Mentoring Service. Jeff vol-unteers with several community organizations including the Harvard Alumni Association and sits on the boards of Tufts Medical Center and The Speakeasy Stage Company in Boston. Jeff has a Lecturer appointment and currently teaches in the HST PhD program at MIT and Harvard Medical School. Jeff has an MS from the Harvard/MIT Division of Health Sciences and Technology (HST), an MBA from MIT Sloan, and graduated from Harvard College. He lives in Newton, MA.

Richard BerensonMember of the Executive Board, MAssachusetts Medical Angels Richard Berenson is a member of the Executive Board of MAssachusetts Medical Angels (MA2), an angel investment group with focus and experise in medical startups (devices, diagnostics, therapeutics, health-care IT, accountable care organizations, and so on). Rick is Managing Director of Venzyme Catalyst, LLC, a startup management organization which partners with scientists and management teams to build finan-cable and financed organizations. Through Venzyme, Rick currently serves as CEO of Thermalin Diabetes, LLC (biotech startup developing next generation insulin analogs) and HeartLander Surgical (medical device company developing minimally invasive systems for epicardial delivery of therapies). He also serves on the board of directors of InCytu (immunotherapy devices) and in advisory roles for other clients.

Rick began his career at AT&T Bell Laboratories as a member of technical staff where he helped launch in-ternal ventures. He then spent several years at software startups in the Boston area before joining McKinsey & Company as a management consultant. Subsequently, Rick has been CEO of ActivBiotics (early stage bio-tech), Banton Precision Wood Products (consumer products manufacturer), NewSphere (knowledge man-agement software), Student.Com, Inc. (new media), and TVGrid (technology for the entertainment industry). Rick has also served as COO or CFO for multiple organizations. Over his career he has helped raise more than $60M for early stage companies. Rick received a JD-MBA from Harvard Business and Law Schools in 1984 and is a graduate of Harvard College.


Biographies 21

Ajit BhartiFounder and Chief Scientific Officer, Predictus Ajit Bharti, Ph.D. is the founder and chief scientific officer of Predictus. He also holds a faculty position in the Department of Medicine, Boston University Medical School. He did his Ph.D. in India and post doctoral training at Dana-Farber Cancer Institute, Harvard Medical School, in Donald W. Kufe lab for four years. Sub-sequently he was promoted to instructor at Dana-Farber and continued to work in the area of DNA-damage induced cell signaling in the response to cancer chemotherapy. He has worked for more than ten years to understand the regulation of topoisoemrase I particularly in the response to its inhibitor, camptothecin. This work has led to the development of a predictive marker to stratify the patient population for treatment with camptothecin. He has published more than forty scientific papers in high impact journal including Nature. Currently his lab is working extensively in biomarker discovery and their validation.

Kevin J. BittermanPrincipal, Polaris Venture Partners Kevin joined Polaris in 2004 and focuses on investments in the life sciences. Prior to joining Polaris, Kevin completed his Ph.D. in genetics at Harvard Medical School. His doctoral research focused on the molecular regulation of caloric restriction and on modulation of a novel class of protein deacetylases. Kevin has au-thored papers in several top tier journals, is an inventor on multiple patents and is a cofounder of Genocea Biosciences and Sirtris Pharmaceuticals (GSK). Kevin currently represents Polaris as a Director of Biolex Therapeutics, EPacing Inc., Follica Inc., Genocea Biosciences, Kala Pharmaceuticals, Taris Biomedical, and Visterra. Additionally, Kevin is a Board Observer to Pulmatrix Inc. Prior to obtaining his Ph.D. at Harvard Medical School, Kevin earned a B.A. with Highest Honors from Rutgers College with a major in Biological Sciences and a minor in Philosophy.

Scott BrownVice President, General Counsel and Global Head of NIBR Patents, Novartis Institutes for BioMedical Research Scott joined Novartis in July 2007 as Vice President, General Counsel and Global Head of NIBR Patents for the Novartis Institutes of BioMedical Research, Inc. (“NIBR”) in Cambridge, MA. Prior to joining NIBR, Scott was Vice President, Deputy General Counsel of Millennium Pharmaceuticals, Inc., also in Cambridge, MA. At Millennium Scott supervised legal functions supporting transactions, M&A, clinical trials and intellectual property. Scott’s first in-house position was as Senior Patent Counsel at Genetics Institute, Inc., Cambridge, MA, which eventually became a division of Wyeth. At GI/Wyeth, Scott was responsible for a broad portfolio of low molecular weight and biologics development candidates. Before going in-house Scott was associated with the firms of Kenyon & Kenyon (Washington) and Dorsey & Whitney (Minneapolis). At those firms his practice focused on the full spectrum of intellectual property and litigation practice for pharmaceutical and biotechnology clients. He received his law degree from Indiana University in 1985 and his undergraduate degree in biochemistry and molecular biology in 1982 from Purdue University.


22 Biographies

Angela ChenPhD candidate at Harvard Medical School, going into Roche Global Leadership Program An-Jou (Angela) Chen will be joining Roche’s Perspectives Program, a two-year global leadership devel-opment program with four rotations in different business functions and countries. Prior to joining Roche, she served as co-Chair of the Harvard Biotechnology Club, a student organization aimed to bridge the gap between academia and industry. She was also a 2008 Fellow of the Startup Leadership Program in Bos-ton. Angela interned at Siemens Venture Capital in Boston, the Industrial Technology Research Institute (ITRI) in Taiwan (one of the two largest national research institutes in Taiwan), MediBic Inc. in Japan, (a startup bioinformatics and consulting company that went public in 2003), and tech transfer offices at Stan-ford and Harvard Universities. Angela is a recent PhD in Genetics / Medical Oncology from Ron DePinho Lab, Harvard Medical School; her dissertation work focused on dissecting the biology of glioblastoma - the most malignant form of brain cancer - through mouse modeling and gene discovery, with the goal of dis-covering novel therapy and diagnostics opportunities. She graduated cum laude from Stanford University with a B.A. degree in Human Biology and thesis work on Alzheimer’s disease.

Chip ClarkChief Executive Officer, GenoceaMr. Clark joins Genocea with over 20 years industry experience. Most recently, Chip co-founded and served as Chief Business Officer of Vanda Pharmaceuticals, Inc. Prior to Vanda, Chip was a Principal at Care Capital, LLC, a venture capital firm investing in biopharmaceutical companies, and served in a variety of commercial roles at SmithKline Beecham (now part of GlaxoSmithKline). Mr. Clark holds a B.A. from Harvard University and an M.B.A. from The Wharton School at the University of Pennsylvania.

Bill EdelmanStrategic Advisor, MindChild Medical Inc.Bill Edelman, is a medical device industry executive with over 33 years experience and currently serves as Chairman of the Board for Leviticus Cardio, Ltd., (cardiac assist power systems), Co-Chairman for ETView, Ltd., (TASE: ETVW) (airway management), Chairman of the Board for Medivalve, Ltd., (percutaneous aortic valve placement) and Cardioflow, Ltd., (embolic protection). Mr. Edelman also serves as an Advisor on the Heathcare Board, for Northeast Securities, Inc., a member of the Screening Committee, Medical Devices for Mass Medical Angels, a member of the Advisory Counsel for the Department of Biomedical Engineering at Rensselaer as well as an Advisor to Highland Instruments, Inc., and MindChild Medical, Inc. . Mr. Edelman recently served as COB for PolyTouch, Ltd. (general surgical instrumentation) and Stimatix GI, Ltd., (ostomy products). Previously, Mr Edelman served as President & Chief Executive Officer, TYRX, Inc., a commercial stage venture backed medical device company focused in drug/device implant products for general surgery, electrophysiology and cosmetic surgery. Prior to TYRX, Mr. Edelman held execu-tive level positions at MicroSense International, LLC (bio-sensing), FibraSonics, Inc. (ultrasonic surgical products), NeuroMod, Inc. (neuro-stimulation technologies), St. Jude Medical, Inc. (NYSE: STJ), Pfizer, Inc. (NYSE: PFE), and Baxter International, Inc. (NYSE: BAX). Mr. Edelman graduated with a degree in Biomedical Engineering from Rensselaer Polytechnic Institute. He has been issued 15 U.S. patents and is an applicant on 3 additional pending patent applications.


Biographies 23

Greg ErmanPresident & CEO, HEMSGreg Erman is a serial med-tech entrepreneur. He has been President & CEO of 6 companies including Il-lumasonix, an ultrasound system for vascular surgery; Precision Biopsy, an optical guided prostate cancer biopsy device; Novo Medical, a BIDMC noninvasive neurostimulation platform for chronic pain; Renalworks Medical Corporation, a VC-backed MGH/MIT spin-out which built an implantable hemofilter for ESRD & CHF; MarketSoft Corporation, a VC-backed enterprise software company in the marketing & sales automa-tion field; and Waypoint, a VC-backed industrial B2B eCommerce internet firm. Greg has incubated roughly 250 academic medical research projects over the last 10 years, built 4 companies from scratch, raised about $100M in venture capital, and successfully grown businesses to about $20M in annual revenue. Each of Greg’s 3 VC-backed companies successfully exited to large public companies and generated returns up to 12X investment. Greg holds BSEE and Marketing MBA degrees with high honors from Rutgers University, is a mentor in six different organizations, and sits on numerous boards of directors and advisory boards in-cluding the Harvard University Wyss Institute Accelerator Fund Investment Committee. Greg’s avocations include coastal sailing & racing, tennis, jazz trumpet, and skiing.

Alexandra GlucksmannSenior Vice President of Research and Business Operations, Cerulean Pharma Alexandra Glucksmann is currently Senior Vice President of Research and Business Operations at Cerulean Pharma, which she joined at its founding. Cerulean Pharma is a clinical stage nanopharmaceutical company. Prior to joining Cerulean, she spent 13 years at Millennium Pharmaceuticals which she joined in 1993 as one of its first scientists. At Millennium, she held a series of positions with increasing responsibility, ultimately be-coming Vice President of all platform technology groups before moving into a senior role in strategic program management and operations. In this role, she worked closely with the CEO and led company-wide process improvement initiatives and participated in business development and M&A efforts.

During her tenure at Millennium, Alexandra was critical to helping Millennium evolve from a genomics re-search-focused organization to a fully integrated pharmaceuticals company with products on the market. Her division played an integral role in the numerous Millennium large pharma collaborations, which generated over $1.8 billion in funding for the company. She serves on the Board of Directors of Taconic Farms and is the Chair of the Board of Women Entrepreneurs in Science and Technology. She is also a member of the Advisory Council of the Partners Center for Personalized Genetic Medicine.

Alexandra was a post-doctoral fellow at the Massachusetts Institute of Technology and holds a Ph.D. with honors from the University of Chicago.

Manijeh GoldbergChief Executive Officer, Privo TechnologiesManijeh has over 20 years of experience in delivering successes in operation improvement, management, design and rollout of commercial products for health care, IT and telecommunication industries. She has ex-pertise in building and leading winning teams and developing long-term vision while working closely with the team on short-term objectives and milestones. She is the founder and principal of a healthcare startup So-nyaSoft, which specializes in building products and providing services to improve operation and productivity of healthcare firms. Manijeh has managed product development in large and small companies. She has led global development teams and has successfully commercialized many medical products. As an executive in several startup companies, she has led cross-functional teams and was instrumental in the fund raising activities. Some of her product development projects involve companies such as Boston Children’s Hospital, Medical Services Company, Boston Scientific, Moulton Financial Strategic Partners, Hemedex Perfusion Monitoring and Nortel Networks. Ms. Goldberg has masters degree from Harvard and MIT in Biomedical


24 Biographies

Enterprise and Health Sciences and Technology. She also has received her graduate degree in computer science and has an MBA from MIT Sloan. She is a member of Engineering Honor Society, MIT entrepreneur-ship club and the VCPE club. She was recently elected as “MIT Graduate Woman of Excellence.” and was the winner of the “MIT 100K Best Product and Services Award in 2010.

Andy GoldenScientist & Engineer, Daktari DiagnosticsAndy Golden is currently a scientist/engineer at Daktari Diagnostics, which is a startup focused on develop-ing diagnostics that address needs in global health. He did a postdoc at Novartis in collaboration with Fluxion Biosciences, following a PhD in Biomedical Engineering in Joe Tien’s lab at Boston University. Before gradu-ate school, Andy worked in intellectual property at two dot-com startups.

Jeremy HalpernChairman, The Capital Network and Partner, Nutter McClennen & Fish LLPJeremy Halpern, is a Partner, and the Director of Business Development, Emerging Companies Group, at Nutter McClennen & Fish LLP, a large Boston-based law firm. As a former entrepreneur, Mr. Halpern con-centrates on connecting with and supporting the Entrepreneurial Ecosystem in New England, working with current entrepreneurs, angel investors, venture capitalists, corporate strategic partners, trade organizations and local, State and Federal agencies. Concurrently, Mr. Halpern serves as the Chairman of The Capital Network, a Boston-based non-profit that provides education to entrepreneurs seeking early stage capital, and as a Professor of Entrepreneurial Leadership at Tufts University. Mr. Halpern is also a Connector in the Boston World Partnership, and a co-founder of BostonIDEA a group which fosters community and relation-ships among the entrepreneurial ecosystem in the Boston’s Innovation District. Previously, Mr. Halpern was the Managing Director of Evolution Advisors LLC, a Boston based strategic transaction advisory firm, and the Co-Founder and Executive Vice President of Business Development for MobileTek Corporation, a developer of PC based applications enabling smarter mobility for consumer mobile devices. Prior to that, Mr. Halpern practiced corporate law with other national law firms in Boston and Los Angeles. Mr. Halpern received his B.A., summa cum laude, Phi Beta Kappa, from the University of California, Berkeley, and his J.D. from the University of California at Los Angeles. Prior to law school, Mr. Halpern spent two years as the Executive Chairman of a concert and special events production company. Mr. Halpern participates with or is a mem-ber of MIT’s Venture Mentoring Service, MassTLC, MDG, E-NET, ACG, REBN-East, MITX, Web Innovators Group and MobileMondays.

Michael W. Henry Vice President, Business Development, Athena Diagnostics Inc., Michael W. Henry is Vice President, Business Development, at Athena Diagnostics Inc., a part of Quest Diag-nostics. He has over 20 years of experience in biotechnology business development. At Athena, he collaborates with gene hunters who discover new disease genes, launches new genetic tests, and serves on the senior lead-ership team that sold Athena to Fisher Scientific for $283 million in 2006, and to Quest for $740 million in 2011. Previously, Mr. Henry served as Vice President, Business Development, at Avant Immunotherapeutics Inc., now merged with Celldex.

Prior to Avant, he worked in academic medical centers, serving as Senior Director, Licensing and Ventures, at University of Massachusetts Medical School, and Director, Technology Transfer, at Children’s Hospital of Phila-delphia. Prior to CHOP, he served as Manager, New Business Development, at Allelix Inc., Mississauga, Ontario. Recognized as a National Science Foundation Fellow as a PhD student at University of California Berkeley, Mr. Henry received an MBA and an MS from University of California Berkeley, and a BS from University of Michigan.


Biographies 25

Andrew JayInvestment Partner, Siemens Venture CapitalDr. Andrew Jay is Fund Head for the Medical Solutions Fund. Within the Med Fund Portfolio, he serves on the Board of Directors at U-Systems, and RadPharm. He previously sat on the board of Molecular Insight Pharmaceuticals and overseas the investments in MDdatacor, Zonare, Lifemasters and previously managed the Sequenom investment. Prior to joining Siemens, Andrew was an I. I. ranked analyst following the medical technology industry at Alex Brown and Wachovia Securities. Sectors under coverage included imaging, or-thopedics, cardiovascular, vision, diabetes, and neurologic devices. During his career, he was instrumental in raising over $2 billion in equity capital for over 30 emerging growth medical technology companies including Boston Scientific, Perclose, Masimo, MediSense and Natus. He published over 10,000 pages of research in-cluding thought leading pieces on neurology, orthopedics and an early introduction to the then emerging field of drug coated stents. Dr. Jay’s prior experience includes leading consulting projects for Arthur D. Little and running his substantial dental practice. He has a Bachelor of Science from Rensselaer Polytechnic Institute, a DMD from the University of Pennsylvania and an MBA from the Kellogg School at Northwestern. Outside of the office Andrew is the founding Director of the Massachusetts Oyster Project.

Julius KnowlesHead, Platforms, Strategic Alliances, Novartis Julius (Jay) Knowles is Head, Platforms, Strategic Alliances for Novartis, responsible for creating technology-based and drug discovery collaborations. Previously, Mr. Knowles was founder and President of Novalar Pharmaceuticals, a specialty pharmaceutical company that recently launched their first drug. Prior to this, he was Vice President, Business Development, at Structural Genomix, and Director, Research and Develop-ment Planning at Vertex Pharmaceuticals. He has an MBA in Finance from Wharton Business School, and an M.Sc. from UC Berkeley in Chemistry.

Jennifer KingSenior Director Scientific Licensing, Shire HGT

Jenn, a Senior Director of Scientific Licensing within business development, joined Shire’s Human Genetic Therapies division (Shire HGT) in February 2006. Prior to joining the business development team she served in the Shire HGT commercial organization as the Global Brand Director for the MLD program and as the Director of New Products, and was responsible for providing commercial guidance to development and research stage projects, as well as evaluating the commercial attractiveness of business development op-portunities. Before joining Shire, Jenn held a variety of roles in Market Research, Marketing and Medical Af-fairs at Millennium Pharmaceuticals; most notably as a member of the core US launch team for VELCADE®. Jenn received her BS in Biology from the Massachusetts Institute of Technology, her Ph.D. in Developmental Biology from Stanford University School of Medicine and her MBA from Northeastern University.


26 Biographies

Stan LapidusFounder, President, and CEO, SynapDxStan Lapidus is the Founder, President, and CEO of SynapDx, a new company developing diagnostic tests for the early detection of autism. Mr. Lapidus is an experienced life-science entrepreneur. Previously, Stanley was Co-Founder and Chairman of Helicos BioSciences. In 1995 he founded EXACT Sciences Corporation (NASDAQ: EXAS), an applied genomics company that develops and markets non-invasive, DNA-based methods for early detection of colorectal and other common cancers. He served as the CEO from 1995 to 2001 and Chairman of EXACT Sciences’ Board of Directors from 2000 until the end of 2005. Prior to EXACT, Mr. Lapidus founded Cytyc Corporation (NASDAQ:CYTC) and was President and CEO from 1987 through 1994. In addition to his entrepreneurial activities, Mr. Lapidus holds academic appointments in the Pathology Department at Tufts University Medical School and MIT’s Sloan School of Management. He earned a BSEE from Cooper Union. He has served as a trustee of Cooper Union since 2002. Mr. Lapidus holds 31 issued patents.

Christopher LeoDirector, Back Bay Life Science AdvisorsChristopher Leo, Ph.D., Director, joined Back Bay from Genzyme, where he led strategic planning projects for the company’s $2 billion Personalized Genetic Health (Cerezyme, Fabrazyme, Myozyme) and $500 million Biosurgery (Synvisc, Sepra) business units. Prior to Genzyme, Chris was a Director with Leerink Swann’s Strategic Advisory group, where he led assignments comprising commercial, R&D, and growth strategies for both big pharma/med-tech and emerging growth clients. Chris was also a Principal in Wood Mackenzie’s life science consulting practice, and prior to that, was Director of the Belfer Cancer Genomics Center at the Dana Farber Cancer Institute. Dr. Leo completed his doctorate in Biochemistry and Molecular Pharmacology at the University of Massachusetts Medical School, a post-doctoral fellowship in the Department of Pathology at Harvard Medical School, and earned his undergraduate degree at Holy Cross College.

Ali MunawarFounder, NoviraAli Munawar is the founder of an antiviral drug discovery company developing a first-in-class, antiviral ap-proach that is applicable to all medically relevant viruses. The company has two compounds in preclinical development that treat HIV and HBV infections respectively. Raised $1.2MM+ in VC and attracted successful pharmaceutical executives to lead the drug discovery program. His prior background includes technology consulting as well as conducting biomedical research at Harvard and MGH. Ali discovered and validated a novel class of antiviral drug targets as a researcher that lead to the founding of Molecmo (now Novira) at the age of 23. He is the recipient of the Gates foundation grant for novel anti-HIV drug development, and holds the distinction of being the youngest Pakistani biotech entrepreneur. Ali holds a Bachelors from Ithaca Col-lege and a Masters from Harvard University. He turned down Columbia Medical School to pursue his dream of starting his biotech company. He was selected as a 2011 Fellow to the Startup Leadership Program.


Biographies 27

Imran Nasrullah Chief Business Officer, Massachusetts Biotechnology Council Imran Nasrullah has more than 15 years experience biotechnology. Imran has spent over 12 years in BD&L in both corporate and academic spheres. Imran brings this experience to the MBC as Chief Business Officer of the MBC. Prior to the MBC, Imran worked for Genzyme Corporation, Millennium Pharmaceuticals, Dana Farber Cancer Institute and the Mayo Clinic; all in the business development and licensing capacity. Imran’s experience extends to having negotiated in-licenses and out-licenses in therapeutics, diagnostics, and tech-nology platforms; as well as negotiated and executed complex and varied agreements with biopharmaceuti-cal, academic, and government entities thereby enhancing R&D activities, acquiring strategic assets, accel-erating product and service launches. In his BD&L role. Imran led teams charged with identifying, evaluating, and pursuing all stages of technology, early stage NCEs, NMEs, and diagnostic tests for acquisition, launch and out-license. Imran possesses proven leadership, scientific acumen, legal and financial savvy, skillful negotiations, and articulate communications skills. Imran leverages critical thinking, adept negotiations and sophisticated quantitative tools to compare business and technology opportunities, structure and negotiate business deals, analyze intellectual property and financial exposure for drug development programs, tech-nology platforms and new diagnostic services. Imran has his Master’s of Science degree from the University of Colorado, Boulder, in exercise biochemistry, and his Juris Doctor, from Suffolk University Law School in Boston, MA.

Pamela NortonVP of Industry Relations and Programs, Massachusetts Life Sciences CenterPamela Norton is the new VP of Industry Relations and Programs at the Massachusetts Life Sciences Cen-ter. Ms. Norton has had a vibrant 30 year career in the medical industry where she is well known for her insight around the future of new medical innovations and her ability to bring together critical stakeholders to help make change happen. Early in her career she was a biomedical engineer at Johnson and Johnson followed by more than a decade at Arthur D. Little where she served as a global partner in the health indus-tries practice helping leading companies define and execute their growth strategies. More recently, Pamela was a director at IMS Consulting working with pharmaceutical players and financial institutions determining value of medical innovations. At the Massachusetts Life Sciences Center, Pamela will support life sciences companies through administration of programs to accelerate their growth and catalyze partnerships critical to the evolution of the state’s life sciences ecosystem.

Eric OlsonVice President and Program Leader, Vertex Pharmaceuticals Incorporated Eric Olson, PhD, is a Vice President and Program Leader at Vertex Pharmaceuticals Incorporated in Cam-bridge, MA, where he works on cystic fibrosis and antibiotic drug discovery and development programs. He co-leads the Vertex and the CF Foundation Therapeutics Joint Development Committee that provides over-sight and strategy for development of two CF compounds: VX-770, a CFTR potentiator currently in Phase 2, and VX-809, a CFTR corrector currently in Phase 1. Prior to joining Vertex, he was at Warner-Lambert (now Pfizer) for 11 years and Upjohn Pharmaceuticals (now Pfizer) for six years, focusing on bacterial gene expression and new antibiotic discovery. His formal training is in Microbiology with a BS from the University of Minnesota, a PhD from the University of Michigan, and post-doctoral studies at McGill University.


28 Biographies

Christopher M. PalatucciFounder, Palatucci Executive Search, LLC.Dr. Chris Palatucci is the founder of Palatucci Executive Search, LLC. (PES), a rapidly growing executive search firm focused on C-level engagements in the Life Sciences and ‘bio-related’ Cleantech industries. Prior to founding PES, Chris was the Life Sciences Practice Leader at Polachi, a leading executive search firm, and successfully built the new practice area for the firm. Previously, he held senior management roles at Interleukin Genetics, Inc. and the Athena Diagnostics division of Elan Pharmaceuticals. Dr. Palatucci also conducted strategic analysis on a wide range of therapeutic and other products in multiple disease areas for biotech and pharma clients at Kendall Strategies / Feinstein Partners. Chris has been a frequent invited speaker at the local and national levels on topics ranging from the genetics of neurological and renal disease to public policy issues related to the pharmaceutical and biotechnology industries. He holds two issued US patents with international counterparts. Chris received his undergraduate degree (Biology and Computer Science) from the University of Rochester and his PhD in neuroscience at Clark University. He also con-ducted pre- and post-doctoral research on the vertebrate olfactory system at the Worcester Foundation for Biomedical Research. Chris’s executive search industry experience has been cited in leading publications such as The Washington Post, CIO Magazine, and Mass High Tech. He has successfully concluded senior searches for leading life sciences and cleantech companies.

Sam (Bo) PasternackPartner, Choate Hall & Stewart LLP Sam (Bo) Pasternack is a member of the Intellectual Property Department. Dr. Pasternack obtains both US and foreign patents over a broad range of technologies and renders opinions relating to patent valid-ity, infringement and freedom to operate. He has performed major patent application work for Boston area universities, research organizations and high technology companies. Dr. Pasternack’s technical expertise includes high temperature superconducting materials, semiconductor technology, drug delivery technology, laser physics, medical technology, vibration suppression systems, automatic control systems, and computer hardware and software. In addition, he solicited the first high temperature superconductivity patent issued by the United States Patent and Trademark Office. Dr. Pasternack also represents clients in interferences before the United States Patent and Trademark Office Board of Patent Appeals and Interferences. He is cur-rently involved in a complex, six party interference. Dr. Pasternack’s technical experience includes: Research Assistant, Department of Aeronautics and Astronautics, Stanford University; Senior Engineer, United States Department of Transportation; and Research Associate, Center for Policy Alternatives, Massachusetts Insti-tute of Technology.

Josh Tolkoff Managing Director, Ironwood EquityJosh works at CIMIT, Center for Integration of Medical and Innovative Technology, accelerating the commer-cialization of suitable projects. In addition, he is a Managing Director of Ironwood Equity Fund, a later stage venture investor in healthcare and specialty manufacturing companies. Prior to Ironwood, Josh founded and managed Seedling Enterprises, considered one of the most successful medical device accelerator funds. Josh founded ACT Medical, which became a premier medical device contract developer and manu-facturer. In 10 years he lead ACT’s growth to over $20 million before it was sold to MedSource. Josh started Harbor Medical Devices, a venture backed medical device company. Prior to founding Har-bor, Josh was head of research and development for over 9 years for Medi-Tech, the founding divi-sion of Boston Scientific. He held this role as the company grew from 20 to over 500 employees. He currently is a corporate Director of numerous for-profit growth companies. He is a board member and


Biographies 29

past chair of MassMedic and the advisory board of the Harvard-MIT program in Health Sciences and Tech-nology. He is the founding board chair of Interise, a non-profit helping small urban companies develop and execute a new growth plan. Interise has grown from 1 to over 25 cities through a partnership with the SBA. Josh received a Bachelor degree with concentration in Engineering and Applied Physics from Harvard Col-lege in 1970 and a Masters degree in Mechanical Engineering with a major in BioMechanics from MIT in 1971. Josh lives in Brookline, MA with his wife, Ann Connolly Tolkoff, the co-founder of City on a Hill Charter School. They have 3 children and 4 grandchildren.

Roger TungCo-Founder, President and Chief Executive Officer, Concert Pharmaceuticals, Inc.Dr. Roger Tung, Co-Founder, President and Chief Executive Officer of Concert Pharmaceuticals, Inc., co-founded the Company in April 2006 based on his independent research. Before Concert, Dr. Tung worked in venture-backed start-up and major pharmaceutical companies, including Vertex Pharmaceuticals Inc., where he was a founding scientist and Vice President of Drug Discovery, and Merck, Sharp and Dohme. Dr. Tung co-invented and headed discovery of Vertex’s two commercial HIV protease inhibitor products, Lexiva® and Agenerase®. He has also overseen the discovery of late-stage clinical agents for the treatment of hepatitis C, cystic fibrosis, and other indications. Dr. Tung received his Ph.D. in Medicinal Chemistry at the University of Wisconsin-Madison from Professor Daniel H. Rich.

James H. VelemaPartner, Lathrop & Gage, LLPJames Velema’s practice includes patent preparation and prosecution, due diligence and opinion work in all areas of biotechnology, including biologic therapies, research tools, screening assays, bioprocessing and purification. A particular focus of his work has involved representing clients in the fields of RNA silencing and antibody technology. He assists a wide variety of clients ranging from start-ups and emerging biotechnology companies to large academic research institutions and Fortune 500 biotechnology companies. In addition, James has considerable research experience in industry and academia. He previously served as the IP manager and patent agent at a pharmaceutical company and research associate at a biotech company, and is an inventor who holds several U.S. patents.

Geoff Whitehead Senior Associate, Flagship VenturesGeoff Whitehead joined Flagship Ventures in 2008 as a Senior Associate. Prior to Flagship, Geoff was with PRTM, a worldwide operational strategy management consultancy, most recently as a Manager in their Life Sciences group. At PRTM, Geoff helped create and lead the molecular diagnostics team and managed multiple strategic and operational engagements with leading pharmaceutical, biotechnology, and diagnostics companies. Previously, Geoff worked at Myriad Genetics, where he performed research on identifying dru-gable targets, enhanced DNA sequencing capabilities and performed human genetics analyses for obesity and diabetes. Geoff holds a PhD in Genetics from the Biological & Biomedical Sciences program at Harvard Medical School and a BS in Biochemistry from the University of Utah. His PhD research was done in the laboratory of Professor Mark Keating at Children’s Hospital Boston in the fields of regenerative medicine, genetics and developmental biology. His PhD research, showing fgf20a to be required for initiation of fin re-generation in zebrafish, was published in the journal Science.


30 Biographies


Planning Committee 31

MALSI Day Planning Committee

Chairs

Abi Barrow, MTTC (Co-Chair)Anupendra Sharma, Siemens (Co-Chair)

Imran Nasrullah, MassBio (Co-Chair)

Content

Richard Anders, MA Medical AngelsBob Creeden, Partners HealthCare

Mark Namchuk, Vertex Pharmaceuticals Aaron Sandoski, Norwich Ventures

Marketplace

Lauren Perna, MassBio

Research & Startup Showcase and Logistics

Julia Goldberg, MTTC

Reception

Lauren Laidlaw, MassBioDenise Aronson, Safety Partners, Inc.

Team

Angela Chen, Harvard Biotech Club Mandrita Datta, Harvard Biotech Club

Rakhshita Dhar, MassBioAnkit Mahadevia, Atlas VentureJohn Moor, PrescribableApps

Shyh-Chang Ng, Harvard Biotech Club Kevin O’Sullivan, MA Biotech Incubator

Ashim Subedee, Harvard Biotech Club Ting Ren, Harvard Biotech Club

Tingting Zhang, Harvard Biotech Club

32 Sponsors & Organizers

4th Annual Massachusetts Life Sciences Innovation Day

Sponsors & Organizers 33


Sponsors and OrganizersGold Sponsor ....................................................................................................................... 34

Massachusetts Life Sciences Center ...........................................................................................................34

Silver Sponsor ...................................................................................................................... 35Partners HealthCare Research Ventures & Licensing ...............................................................................35

Conference Supporters ....................................................................................................... 36Lathrop & Gage LLP .................................................................................................................................36Novartis Venture Fund ...............................................................................................................................36Nutter McClennen & Fish LLP .................................................................................................................37Vertex Pharmaceuticals .............................................................................................................................37

Organizers ........................................................................................................................... 38Massachusetts Technology Transfer Center ..............................................................................................38Massachusetts Biotechnology Council ......................................................................................................39TiE, MA2 , CIMIT ....................................................................................................................................40MALSI .......................................................................................................................................................41

In association with .............................................................................................................. 42Harvard Biotechnology Club ...................................................................................................................42Harvard Alumni Entrepreneurs .................................................................................................................42Lemelson-MIT ...........................................................................................................................................42M2D2 .........................................................................................................................................................42MASS-AWIS .............................................................................................................................................42Massachusetts Biomedical Initiatives .......................................................................................................42MassChallenge Inc. ....................................................................................................................................42MassMedic .................................................................................................................................................42Massachusetts Technology Collaborative .................................................................................................42Massachusetts Technology Leadership Council ........................................................................................42NCIIA ........................................................................................................................................................42NEVCA .....................................................................................................................................................42North Shore InnoVentures ........................................................................................................................42OPEN.........................................................................................................................................................42The Bioscience Network ...........................................................................................................................42The Capital Network .................................................................................................................................42WEST ........................................................................................................................................................42University of Massachusetts .......................................................................................................................42



Gold Sponsor



Silver Sponsor



Conference Supporters

C A L I F O R N I A P C O L O R A D O P I L L I N O I S

K ANSAS P MASSACHUSET TS P MISSOURI

N E W Y O R K P W A S H I N G T O N D C *

* L AT H R O P & G A G E D C , P L L C - A F F I L I AT E

{ 8 0 0 } 4 7 6 - 4 2 2 4

w w w . l at h r o p g a g e . c o m

N a t i o N a l f i r m . m i d w e s t va l u e .s m

we salute this opportunity for the science and

business communities to connect and collaborate.

the choice of a lawyer is an important decision and should not be based solely upon advertisements. For more information, contact giulio Deconti at (857) 300-4000.



Nutter in the Life Sciences Nutter McClennen & Fish LLP has a long track record of working with clients in the life sciences throughout the enterprise lifecycle to meet their legal and strategic needs. With in-depth legal and scientific credentials as well as experience in executive, in-house counsel, and other industry capacities, our attorneys take responsibility for knowing the client’s needs and objectives, and for partnering to achieve successful outcomes and competitive advantage. Our roster of life sciences clients is international and diverse, including:

U.S. and multinational medical device, biotechnology and pharmaceutical companies

Renowned medical institutions and research universities

Major hospitals and other health care providers

Emerging growth companies

Venture capital firms and entrepreneurs Nutter’s experience and knowledge cover a wide range of technologies and products, from medical devices such as implants, surgical instruments, and diagnostic and therapeutic products, to research instrumentation and tools, to biopharmaceuticals ranging from functional genomics and immunology to diagnostics and gene therapy. Our services include:

Corporate matters, financing and securities

Intellectual property and IP litigation

Government regulation, including clinical trials, SEC and marketing/pricing compliance, and privacy

Health care

Litigation, including product liability defense, commercial disputes, white collar and employment

Nutter Strategic Planning Program A Boot Camp for Technology Entrepreneurs and Early Stage Companies

The Nutter Strategic Planning program is designed to meet the needs of start-up and early stage companies that are ready to undergo sophisticated strategic planning and take important next steps in the formation and growth of their businesses. The program consists of one-on-one customized counseling sessions between the selected company and select Nutter attorneys.

Seaport West 155 Seaport Boulevard

Boston, MA 02210 617.439.2000



The Massachusetts Technology Transfer Center is funded by the Commonwealth of Massachusetts. Its goal is to support technology transfer activities from public and private research institutions to companies in Mas-sachusetts. To achieve this goal, the Center works with technology transfer offices at Massachusetts research institutions; faculty, researchers, and students who have commercially promising ideas; and companies across the Commonwealth.

_______________________________________________________________________________

The Center: facilitates and accelerates technology transfer between research institutions and Massachusetts • companies;promotes collaboration between research institutions and the Commonwealth’s technology in-• dustry; assists in the growth of Massachusetts companies, including startups, by enhancing technologi-• cal leadership; andsupports regional and statewide economic development priorities. •

_______________________________________________________________________________

The Center supports the commercialization of research technologies through a variety of programs:

The Center provides mentoring to researchers who believe they have a technology that could serve as the basis of a new company. The process includes the development of a business presentation for an expert board of external reviewers.

Commercialization and Entrepreneurial Education seminars and workshops enable researchers to understand the process of commercializing technologies.

Expert technology reviews provide opportunities for Massachusetts research institutes to have external industry experts evaluate technologies and give advice regarding their commercial potential.

Technology Forums allow investors and potential corporate partners to meet with companies formed around technologies developed in Massachusetts research institutes.

www.MaTTCenter.org

www.MassTechPortal.org

[email protected]



UPCOMING EVENTS

June 27-30, 2011 BIO International Convention, Washington, D.C. Visit the Massachusetts Pavilion!

September 7-9, 2011 BioPharm America at Westin Waterfront

September 9, 2011 MassBioEd Foundation Golf Classic at The Pinehills

One Cambridge Center | Cambridge, MA 02142 | TEL: 617-674-5100 | FAX: 617-674-5101 www.massbio.org



We are motivated to leverage what is truly unique about MA

“If I stand in the middle of Mass Ave Bridge, and walk 1 mile in either direction, I have everything I need to start a billion dollar life sciences company”

The Massachusetts Life Sciences Start-up Initiative (MALSI) is a collaborative group of public and private entities that work with emerging biotech and biomed companies. The prime aim of MALSI is to ensure that every life sciences entrepreneur or researcher who has a commercializable idea has easy and rapid access to the vast network of organizations and individuals who can help them realize their dreams. The Massachusetts Technology Transfer Center, Mass MEDIC, TiE Boston, and MassBio have partnered to present the Massachusetts Life Sciences Innovation Day.

In case you have any questions, please contact the MALSI Co-chairs:

Please join our MALSI Group on LinkedIn.com

Anupendra Sharma Investment Partner, Siemens Venture [email protected]

Dr. Abigail A. BarrowDirector, Massachusetts Technolgy Transfer [email protected]



The Organizing Committee thanks our Non-Profit Affiliates:


Poster Presenters 43

Poster PresentersAbazyme LLC ......................................................................................................................... 45

Jim Dasch, CSO and Co-Founder

AcuityBio Inc. ......................................................................................................................... 45Jay Schwartz, CEO

Advirna ................................................................................................................................... 45Alexey Wolfson, CEO

Beth Israel Deaconess Medical Center .................................................................................... 45 Ahmed Ibrahim, MD at Surgery & Plastic Surgery

Boston University .................................................................................................................... 45Lisa Marie Sturk, Director of Business Development

Boston University .................................................................................................................... 46Lisa Marie Sturk, Director of Business Development

Brandeis University ................................................................................................................. 46Jared Auclair, Postdoctoral Research Fellow

Brandeis University ................................................................................................................. 46Ken Sugino, Researcher

Cellgenex Diagnostics ............................................................................................................ 46Eric Evans, CEO

Cellthera, Inc. & Worcester Polytechnic Insitute ................................................................... 46Christopher Malcuit, Chief Operating Officer & Research Assistant Professor

CMB Science Inc. ................................................................................................................... 47Scott Wharram, President

Diagnostics for All .................................................................................................................. 47Matthew Stewart, Senior Scientist

Harvard Medical School ......................................................................................................... 47Shuqi Wang, Postdoctoral Research Fellow

Harvard University .................................................................................................................. 47Bjorn Millard, Fellow, Systems Pharmacology

HepatoChem ........................................................................................................................... 47Marc Bazin, President


44 Poster Presenters

Karyopharm Therapeutics....................................................................................................... 47Dilara McCauley, Senior Director, Product Leadership

Massachusetts General Hospital ............................................................................................. 48Suraj Patel, Fellow, General Surgery

Massachusetts Institute of Technology ................................................................................... 48Shawn Kelly, Visiting Scientist

Pharyx Inc. ............................................................................................................................... 48Paolo Boccazzi, Chief Scientific Officer

Physical Sciences Inc. .............................................................................................................. 48David Rosen, Group Leader, Clinical Technologies

Renu Therapeutics LLC ......................................................................................................... 48Kent Thompson, Founder

Seign LLC ............................................................................................................................... 48Lawrence Casha, Director of Research

University of Massachusetts-Amherst ..................................................................................... 49Lakis Mountziaris, Professor and Head, Department of Chemical Engineering

Worcester Polytechnic Institute .............................................................................................. 49Christopher Lambert, Research Associate Professor

Worcester Polytechnic Institute .............................................................................................. 49George Pins, Associate Professor, Department of Biomedical Engineering

Worcester Polytechnic Institute .............................................................................................. 49Pam Weathers, Professor

Worcester Polytechnic Institute .............................................................................................. 49Pam Weathers, Professor

Worcester Polytechnic Institute, Columbia University & Stony Brook University ............... 50Glenn Gaudette, Associate Professor

Wyss Institute, Harvard University ......................................................................................... 50Dan Huh, Technology Development Fellow

Wyss Institute, Harvard University ......................................................................................... 50Michael Super, Senior Staff Scientist

Wyss Institute, Harvard University ......................................................................................... 50Kyung-Jin Jang, Postdoctoral Research Fellow


45

Abazyme LLC Presented by: Jim Dasch, CSO and Co-Founder [email protected] Poster Title: Developing Engineered Monoclonal Antibodies (eMABs™) for the Research Mar-ketplace

AcuityBio Inc. Presented by: Jay Schwartz, [email protected] Poster Title: Prevention of Tumor Recurrence Through Localized Drug Delivery

Advirna Presented by: Alexey Wolfson, [email protected] Poster Title: Self-deliverable RNAi technology for specific gene knockdown in mammalian cells

Beth Israel Deaconess Medical Center

Presented by: Ahmed Ibrahim, MD at Surgery & Plastic Surgery [email protected] Poster Title: A New Neuroprosthetic Device for Electrochemical Activation and Inhibition of Neuromuscular Systems

Boston University Presented by: Lisa Marie Sturk, Director of Business [email protected] Poster Title: Metabolite-enabled eradication of bacterial persisters by aminoglycosides



Boston University Presented by: Lisa Marie Sturk, Director of Business [email protected] Poster Title: Engineered bacteriophage targeting gene networks enhance antibiotic potency

Brandeis University Presented by:Jared Auclair, Postdoctoral Research [email protected] Poster Title: Identifying Pharmacological Chaperones that Promote Survival in Mouse Models of ALS

Brandeis University Presented by: Ken Sugino, [email protected] Poster Title: A Novel, Low Cost, Highly Sensitive Form of Suppression PCR

Cellgenex Diagnostics Presented by: Eric Evans, [email protected] Poster Title: Identifying a Patient Segment That Will Not Restenose After Bare Metal Stent Placement

Cellthera, Inc. & Worcester Polytechnic Insitute Presented by: Christopher Malcuit, Chief Operating Officer & Research Assistant Professor [email protected] Poster Title: Functional Regeneration of a Large-Scale Skeletal Muscle Defect Using Dediffer-entiated Fibroblasts and a Microthread-Based Scaffold Delivery System


47

CMB Science Inc. Presented by: Scott Wharram, [email protected] Poster Title: Biodegradable Wound Dressings for Skin Regeneration

Diagnostics for All Presented by: Matthew Stewart, Senior [email protected] Poster Title: Low-cost, rapid diagnostics for improving agricultural and livestock productivity

Harvard Medical School Presented by: Shuqi Wang, Postdoctoral Research [email protected] Poster Title: Microfluidics-based immunosensor for rapid HIV-1 viral load detection

Harvard University Presented by: Bjorn Millard, Fellow, Systems [email protected] Poster Title: Adaptive informatics for multi-factorial and high content biological data

HepatoChem Presented by: Marc Bazin, [email protected] Poster Title: HepatoChem: Metabolite Production Platform

Karyopharm Therapeutics Presented by: Dilara McCauley, Senior Director, Product [email protected] Poster Title: Preclinical Development of Small-Molecule CRM1 Inhibitors as a Novel Therapy for the Treatment of Hematological and Solid Malignancies



Massachusetts General Hospital Presented by: Suraj Patel, Fellow, General [email protected] Poster Title: Engineering a Hepatoprotective Strategy in Drug Development

Massachusetts Institute of Technology Presented by: Shawn Kelly, Visiting [email protected] Poster Title: A 200+ Channel Retinal Prosthesis

Pharyx Inc. Presented by: Paolo Boccazzi, Chief Scientific [email protected] Poster Title: Integrated Microfluidic Bioreactor Arrays

Physical Sciences Inc. Presented by: David Rosen, Group Leader, Clinical [email protected] Poster Title: Real-time Dosimetry-guidance for Photodynamic Therapies

Renu Therapeutics LLC Presented by: Kent Thompson, [email protected] Poster Title: Cardioprotective Biologics Based on Myocardial Ischemia-induced Secretory Proteins

Seign LLC Presented by: Lawrence Casha, Director of [email protected] Poster Title: Ajjolos, The System for Passive Stretching


49

University of Massachusetts-Amherst Presented by: Lakis Mountziaris, Professor and Head, Department of Chemical [email protected] Poster Title: Platform Technology for Rapid Quantitative Detection of Biomolecular Inter-actions using Novel Optically-Responsive Semiconductor Nanocrystals

Worcester Polytechnic Institute Presented by: Christopher Lambert, Research Associate [email protected] Poster Title: Chemical Surface Modification for Tissue Regeneration and Sensing Applica-tions

Worcester Polytechnic Institute Presented by: George Pins, Associate Professor, Department of Biomedical [email protected] Poster Title: Biological Sutures for Efficient Stem Cell Delivery

Worcester Polytechnic Institute Presented by: Pam Weathers, [email protected] Poster Title: From plant to patient: edible delivery of a broad spectrum drug

Worcester Polytechnic Institute Pam Weathers, [email protected] Poster Title: A new bioreactor for adherent cells and tissues



Worcester Polytechnic Institute, Columbia University & Stony Brook University

Presented by: Glenn Gaudette, Associate [email protected] Poster Title: Development of a Biological Pacemaker

Wyss Institute, Harvard University Presented by: Dan Huh, Technology Development [email protected] Poster Title: A Human Breathing Lung-on-a-Chip

Wyss Institute, Harvard University Presented by: Michael Super, Senior Staff [email protected] Poster Title: Development of a Device for Rapid Diagnosis of Sepsis

Wyss Institute, Harvard University Presented by: Kyung-Jin Jang, Postdoctoral Research [email protected] Poster Title: Human Kidney Proximal Tubule-on-a-Chip for Drug Transporter Studies and Nephrotoxicity Assessment


Innovator's Marketplace Exhibitors 51

Innovators’ Marketplace Exhibitors


52 Innovator's Marketplace Exhibitors

Life Science Products and Services

Accounting Management Solutions ...........................................................www.amsolutions.net

ALPCO Diagnostics .......................................................................................... www.alpco.com

Ash Stevens, Inc. ......................................................................................www.ashstevens.com

MedChem Partners .......................................................................www.medchempartners.com

Middlesex Gases Technoligies Inc. ................................................. www.middlesexgases.com

pION INC ....................................................................................................... www.pion-inc.com

Pressure Bioscience Inc. .......................................................... www.pressurebiosciences.com

Toxikon Corp ....................................................................................................www.toxikon.com

Vertex ................................................................................................................... www.vrtx.com

Worcester Polytechnic Institute ............................................................................. www.wpi.edu

Entrepreneurship Support

Massachusetts Life Sciences Center ..............................................www.masslifesciences.com

MTTC ...........................................................................................................www.mattcenter.org

MBC ................................................................................................................ www.massbio.org

MassMedic ...............................................................................................www.massmedic.com

MALSI ............................................................................ www.linkedin.com/groups?gid=113959

Harvard Biotechnology Club ................................................................. www.thebiotechclub.org

Harvard Alumni Entrepreneurs ....................................... www.harvardalumnientrepreneurs.org

HBA .................................................................................................................www.hbanet.org/

Lemelson-MIT Program ................................................................................ web.mit.edu/invent

MASS-AWIS ................................................................................................www.mass-awis.org

Massachusetts Biomedical Initiatives ...................................................... www.massbiomed.org

Massachusetts Medical Device Development Center (M2D2) ...................www.uml.edu/m2d2

Massachusetts Technology Leadership Council ............................... www.masstechleaders.org

Massachusetts Technology Collaborative .................................................... www.masstech.org

MVVF ....................................................................................................................www.mvvf.org

NCIIA .................................................................................................................... www.nciia.org

North Shore InnoVentures ..................................................................................... www.nsiv.org


Innovator's Marketplace Exhibitors 53

OPEN ............................................................................................ www.open-newengland.com

TiE ................................................................................................................www.tie-boston.org

The Bioscience Network ............................................................www.thebiosciencenetwork.org

WEST ..............................................................................................................www.westorg.org

Angel & Startup CEO Bar

Funding

CIMIT .................................................................................................................... www.cimit.org

Mass Medical Angels ........................................................................www.massmedangels.com

MassChallenge Inc. ..............................................................................www.masschallenge.org

New England Venture Capital Association ............................................www.newenglandvc.org

Novartis Venture Fund ............................................................... www.venturefund.novartis.com

Partners HealthCare Research Ventures & Licensing ................................www.rvl.partners.org

The Capital Network – TCN ..............................................................www.thecapitalnetwork.org

Professional Services

Lathrop & Gage LLP ................................................................................www.lathropgage.com

Nutter, McClennen & Fish LLP ..........................................................................www.nutter.com

Sallop Insurance Company ...............................................................................www.sallop.com


54 Innovator's Marketplace Exhibitors

Notes

dr. abigail a. barrow anupendra sharma imran nasrullah co ... · pitches that led to series a round...

Documents